Recursion Pharmaceuticals amends bylaws to enhance proxy disclosure and conform to Delaware law

RECURSION PHARMACEUTICALS, INC.

Bylaw amendments enhance procedural mechanics and disclosure for stockholder director nominations and proposals (except Rule 14a-8).
Amendments incorporate universal proxy rules per Rule 14a-19 and conform to recent DGCL changes.
Updated provisions regarding Board committees, officers, written consent, indemnification, and exclusive forum.
Compensation recovery policy reflected in limitation on indemnification.
Effective January 25, 2024; filed as Exhibit 3.1.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

RECURSION PHARMACEUTICALS, INC.: Amended and restated Bylaws to enhance stockholder proposal procedures, adopt universal proxy rules, conform to DGCL, update director/officer provisions, and make other revisions (effective 2024-01-25).

Change: bylaw amendment
Effective: 2024-01-25

Exact text from the filing

On January 25, 2024, the Board of Directors (the “Board”) of Recursion Pharmaceuticals, Inc. (the “Company”) amended and restated the Company’s Bylaws (the “Bylaws”), effective immediately.

View on SEC.gov

40 governance changes filed in the last 30 days. Browse all governance changes →

RECURSION PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001601830-24-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.